Tag: oral immunotherapy (OIT)

Omalizumab

Study: Treatment with Omalizumab Raises Tolerance in Patients with Severe Food...

Patients reached full tolerance for 70.4% of the tested foods which were reintroduced to the patients’ diet without the need for OIT.
Child Thinking

Positive Mindset About Side Effects of Peanut OIT Improves Outcomes

Framing side effects as positive signs of healing significantly reduced anxiety in young children.
AR101 Delayed by Gov't Shutdown

Government Shutdown Delays Review of AR101 Peanut Oral Immunotherapy Candidate

The FDA has shelved consideration of the drug until funding is restored.
AR101

Aimmune Submits FDA Application to Offer AR101 for the Treatment of...

“We have requested FDA Priority Review and look forward to working with the agency to bring what could be the first approved treatment in food allergy to patients as quickly as possible.”
Eggs

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Moo

Test is 87% Accurate at Determining Outcome to Milk OIT

Using a growing database of patient reactivity signatures can better predict milk-allergic patient outcomes compared to traditional methods.
Peanuts

Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for...

An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
AR101

New Treatment to Protect People with Peanut Allergies Ready for FDA...

"Two thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after 9 to 12 months of treatment."
Christopher Ryan and Friends

Teen Undergoes Peanut OIT to Join Marines

“I’m not taking no for an answer...."
Wheat

Mount Sinai Researchers Find Wheat Oral Immunotherapy to Be Therapeutic for...

First multicenter rigorous clinical trial yields promising results.

Connect with Us

36,042FansLike
94FollowersFollow
300FollowersFollow
2,462FollowersFollow
5,302FollowersFollow
37SubscribersSubscribe